Small molecules and targeted therapies in distant metastatic disease

Keyphrases

• Chemotherapy 100%
• Targeted Therapy 100%
• Distant Metastasis 100%
• Melanoma 100%
• Small Molecule Therapy 100%
• Molecular Profiling 50%
• Targeted Agents 50%
• Clinical Development 50%
• Combination Therapy 50%
• Cell Signaling Pathways 50%
• Mammalian Target of Rapamycin (mTOR) 50%
• Specificity Protein 1 50%
• Dasatinib 50%
• B-cell Lymphoma 2 (Bcl-2) 50%
• Patient Survival 50%
• Anti-apoptotic 50%
• Anti-apoptotic Proteins 50%
• Genetic Changes 50%
• Sunitinib 50%
• KIT mutation 50%
• Biological Agents 50%
• Antisense Oligonucleotides 50%
• Vascular Endothelial Growth Factor Receptor (VEGFR) 50%
• Receptor Tyrosine Kinase Inhibitor 50%
• Sorafenib 50%
• Imatinib 50%
• Heat Shock Protein 90 (Hsp90) 50%
• Metastatic Melanoma 50%
• AZD6244 50%
• Axitinib 50%
• New Targeted Drugs 50%
• B-Raf 50%
• Rational Use 50%
• PLX4032 50%
• Everolimus 50%
• New Agents 50%
• Multikinase Inhibitor 50%
• Elesclomol 50%
• Oblimersen 50%
• Analytical Techniques 50%
• Deforolimus 50%
• PD0325901 50%
• RAF265 50%
• Temsirolimus 50%
• Tanespimycin 50%
• MEK Pathway 50%
• G3139 50%

Medicine and Dentistry

• Metastatic Carcinoma 100%
• Targeted Therapy 100%
• Antiapoptotic 100%
• Oblimersen 100%
• Chemotherapy 100%
• Melanoma 100%
• Molecular Profiling 50%
• Gene Mutation 50%
• Combination Therapy 50%
• Mammalian Target of Rapamycin 50%
• Protein 50%
• Dasatinib 50%
• Tyrosine-Kinase Inhibitor 50%
• Clinical Study 50%
• Protein Tyrosine Kinase 50%
• Sunitinib 50%
• Biological Product 50%
• Imatinib 50%
• Vemurafenib 50%
• Metastatic Melanoma 50%
• Sorafenib 50%
• Selumetinib 50%
• Analytic Method 50%
• Everolimus 50%
• Tanespimycin 50%
• Antisense Oligonucleotide 50%
• Elesclomol 50%
• Oligonucleotide Targeting 50%
• N (2,3 Dihydroxypropoxy) 3,4 Difluoro 2 (2 Fluoro 4 Iodoanilino)benzamide 50%
• Ridaforolimus 50%
• Axitinib 50%
• Temsirolimus 50%
• Heat Shock Protein 90 50%
• Chir 265 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Chemotherapy 100%
• Antiapoptotic 100%
• Metastasis 100%
• Melanoma 100%
• Oblimersen 100%
• Combination Therapy 50%
• Clinical Study 50%
• Dasatinib 50%
• Protein Tyrosine Kinase Inhibitor 50%
• Protein Tyrosine Kinase 50%
• Protein 50%
• Sorafenib 50%
• Imatinib 50%
• Heat Shock Protein 90 50%
• Metastatic Melanoma 50%
• Vemurafenib 50%
• Sunitinib 50%
• Selumetinib 50%
• Axitinib 50%
• Biological Product 50%
• Everolimus 50%
• Elesclomol 50%
• N (2,3 Dihydroxypropoxy) 3,4 Difluoro 2 (2 Fluoro 4 Iodoanilino)benzamide 50%
• Ridaforolimus 50%
• Antisense Oligonucleotide 50%
• Oligonucleotide Targeting 50%
• Chir 265 50%
• Tanespimycin 50%
• Temsirolimus 50%